Functional Consequences of Mutations in Myeloproliferative Neoplasms.

HemaSphere
Stefan N ConstantinescuNicolas Papadopoulos

Abstract

Driver mutations occur in Janus kinase 2 (JAK2), thrombopoietin receptor (MPL), and calreticulin (CALR) in BCR-ABL1 negative myeloproliferative neoplasms (MPNs). From mutations leading to one amino acid substitution in JAK2 or MPL, to frameshift mutations in CALR resulting in a protein with a different C-terminus, all the mutated proteins lead to pathologic and persistent JAK2-STAT5 activation. The most prevalent mutation, JAK2 V617F, is associated with the 3 entities polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), while CALR and MPL mutations are associated only with ET and MF. Triple negative ET and MF patients may harbor noncanonical mutations in JAK2 or MPL. One major fundamental question is whether the conformations of JAK2 V617F, MPL W515K/L/A, or CALR mutants differ from those of their wild type counterparts so that a specific treatment could target the clone carrying the mutated driver and spare physiological hematopoiesis. Of great interest, a set of epigenetic mutations can co-exist with the phenotypic driver mutations in 35%-40% of MPNs. These epigenetic mutations, such as TET2, EZH2, ASXL1, or DNMT3A mutations, promote clonal hematopoiesis and increased fitness of aged hematopoietic s...Continue Reading

References

Feb 26, 1998·The New England Journal of Medicine·A R MoliternoJ L Spivak
Apr 25, 2000·Molecular and Cellular Biology·P SaharinenO Silvennoinen
Apr 11, 2001·Proceedings of the National Academy of Sciences of the United States of America·S N ConstantinescuH F Lodish
Jan 29, 2005·The Journal of Biological Chemistry·Virginie Moucadel, Stefan N Constantinescu
Mar 23, 2005·Lancet·E Joanna BaxterUNKNOWN Cancer Genome Project
Apr 29, 2005·The New England Journal of Medicine·Robert KralovicsRadek C Skoda
Dec 21, 2005·Proceedings of the National Academy of Sciences of the United States of America·Xiaohui LuHarvey Lodish
Aug 8, 2006·Nature Genetics·Song ShiWillis X Li
Mar 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luciana TeofiliLuigi M Larocca
Dec 26, 2007·The Journal of Biological Chemistry·Xiaohui LuHarvey F Lodish
Mar 8, 2008·The Journal of Biological Chemistry·Alexandra DusaStefan N Constantinescu
May 29, 2009·The New England Journal of Medicine·François DelhommeauOlivier A Bernard
Sep 29, 2009·Nature·Mark A DawsonTony Kouzarides
Mar 16, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Erin E MatthewsDonald M Engelman
Aug 16, 2011·Nature Structural & Molecular Biology·Daniela UngureanuOlli Silvennoinen
Sep 6, 2011·The EMBO Journal·Judith StaerkStefan N Constantinescu
Mar 2, 2012·The New England Journal of Medicine·Claire HarrisonGiovanni Barosi
Mar 2, 2012·The New England Journal of Medicine·Srdan VerstovsekHagop M Kantarjian
Jul 24, 2012·Nature Structural & Molecular Biology·Rajintha M BandaranayakeStevan R Hubbard
Aug 8, 2012·Oncogene·W Vainchenker, S N Constantinescu
Jan 30, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jean-Philippe DefourStefan N Constantinescu
Sep 10, 2013·Nature Structural & Molecular Biology·Angela V TomsMichael J Eck
Nov 30, 2013·Chemical Communications : Chem Comm·Lukas LercherChristopher J Schofield
Dec 12, 2013·The New England Journal of Medicine·Thorsten KlampflRobert Kralovics
Dec 12, 2013·The New England Journal of Medicine·J NangaliaA R Green
Dec 25, 2013·Blood·Elisa RumiUNKNOWN Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
May 21, 2014·Proceedings of the National Academy of Sciences of the United States of America·Patrick J LupardusCharles Eigenbrot
Jun 12, 2014·Nature Structural & Molecular Biology·Yibing ShanStevan R Hubbard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.